Introduction
Osteosarcoma, the most common primary malignant bone tumor, commonly arises in the metaphysis of long bones (1) . Normally, osteosarcoma has a moderate rate of incidence, with 10 to 26 cases per million worldwide every year (2) .
The 5-year survival in osteosarcoma in the first half of the 20th century was less than 20% (3) . Amputation of the involved extremity aimed at compartmental resection was initially the mainstay of treatment (4) . The primary target was to decrease the tumor load, although this does not prevent metastasis and pulmonary metastasis via hematogenous spread, which was the major cause of mortality in these patients. In a normal course, osteoblastic cells are responsible for the production of the bony matrix. The same occurs with these osteogenic cells in cancerous bones, the difference being in the maturation and strength of bone matrix thus produced, i.e. the bone matrix of a bone with osteosarcoma is not as strong as that of normal bones (5) . Tumors, regardless of whether they are benign or malignant, can lead to pathological fractures of the involved bone by virtue of their potential to replace normal bony tissues, rendering them weak and prone to fracture. Osteosarcoma has five different histological types and their severity and prognosis varies accordingly. When diagnosed, it is usually in the late stages with high grades of severity, which makes salvage of the involved limbs difficult. Osteosarcomas originate from mesenchymal cells having osteoblastic features. Although the incidence of this bone tumor is low in the general population, unfortunately it is the most often diagnosed and lethal bone cancer in young adults (6) . Osteosarcoma is a highly malignant osteoid-forming spindle cell sarcoma of the bone. Sometimes genetic variations may be linked with an increased risk of osteosarcoma (7) .
The first discovered CCN protein, i.e. CYR61, also known as CNN1, was initially believed to be a classic growth factor. Later studies established that CCN1, instead of being a potent growth factor, also acted as a stimulator for some other growth factors, such as fibroblast growth factor and platelet-derived growth factor (8) .
Though osteosarcoma can occur in any bone, the metaphysis of long bones is a common site of its occurrence (80%-90%), with a particular predilection for distal femoral metaphyses (35%), proximal tibial metaphyses (20%), and proximal humeral metaphyses (10%). In children, osteosarcoma accounts for 5% of all malignant bone tumors, with peak occurrence between the ages of 10 to 24 years (9). When symptomatic, it usually presents with localized pain, swelling, deformity, or a pathological fracture. The most common malignant bone tumors in children are osteosarcomas, which collectively make up 90% of pediatric bone tumors (10) . The CYR61 proteins are composed of extracellular matrix-associated proteins that play crucial roles in skeletal development, wound healing, fibrosis, and cancer (11) . The CYR61 proteins have four conserved cysteine-rich modular domains that trigger the processes of cell adhesion, proliferation, migration, differentiation, and survival via direct binding to specific integrin receptors and heparin sulfate proteoglycans (9) . The effects of these processes are commonly regulated through signaling via integrins, vascular endothelial growth factor, bone morphogenetic protein, Wnt, and Notch pathways. In addition, current studies suggest that CYR61 proteins may affect progression of secondary metastatic bone tumors by moderating the bone microenvironment (11, 12) .
CYR61 is a product of an immediate and early gene that induces cell migration, mediates cell adhesion, enhances growth factor-induced DNA synthesis in fibroblasts and endothelial cells, stimulates chemotaxis of fibroblasts and endothelial cells, and increases the chondrogenesis in mesenchymal cells (13) (14) (15) . The expression of CYR61 protein enhances neovascularization and tumor formation of human tumor cells in immunodeficient mice significantly (16) (17) (18) .
Overall, a better understanding of CYR61 gene protein-regulated pathways in osteoblast/osteoclast can improve our knowledge of the pathogenesis of the disease and can potentially aid in developing CYR61 proteinbased diagnostic marker and therapeutic strategies for the management of osteosarcoma. Therefore, study of the CYR61 protein in patients with osteosarcoma is being considered as a promising biomarker for future research work.
Materials and methods

Specimen collection
Fifty-eight osteosarcoma specimens were collected from the Department of Orthopedic Surgery, King George's Medical University, Lucknow, Uttar Pradesh, India. In such cases, fine-needle aspiration biopsy yielded positive cytology and based on these results, the tissue was diagnosed as osteosarcoma. The 58 cases were diagnosed as osteosarcoma using quantitative, qualitative, and histological grade according to Enneking et al. (19) and Bickels et al. (20) . This study was carried out from May 2011 to March 2015. The study was approved by the institutional ethics committee. Before enrollment in the study, each subject's written informed consent was obtained in response to a fully written and verbal explanation of the nature of the study.
DNA isolation
Samples were collected from 58 biopsy tissues diagnosed as osteosarcoma based on categorized and grading as per the internationally accepted standard. The genomic DNA was extracted by a Fermentas DNA extraction kit (Germany) and stored at -80 °C.
Genomic DNA PCR amplification
Primers for the CYR61 gene were designed using GENE TOOL software. PCR was performed in a gradient thermocycler (ABI, USA) using thin-walled 0.2-mL PCR tubes. The final volume of the PCR reaction mixture was 25 µL, containing 10-40 ng of genomic DNA, 1 pmol of forward and reverse primers, and 2X master mix (ABI, USA) at a concentration of 1X. Amplification was carried out using different primers for different exons (Table 1) and different PCR programs (Table 2) for different exonic regions of the CYR61 gene. A further 5 µL of the amplified product was checked on 2% agarose gel with ethidium bromide staining. 
Variation screening of CYR61 exons by SSCP
Single-strand conformational polymorphism (SSCP) analysis was performed according to Orita et al. (21, 22) with minor modifications. Samples were denatured at 95 °C for 5 min with denaturing dye and immediately transferred to ice. Next, 25 µL of amplified PCR product was loaded along with 25 µL of denaturing dye on 8% polyacrylamide gel. The gel was run in precooled 1X TBE buffer. The gel tank was placed in a cold room at 4 °C and run for 8-10 h at 130 V. DNA on the gel was stained after electrophoresis with silver stain. Electrophoresis mobility shifts in singlestranded or double-stranded DNA products from patients were detected by comparison with DNA products from normal controls run in adjacent lanes ( Figure 1) .
CYR61 variation analysis by sequencing
Amplified fragments of all samples were characterized by automated sequencing. The PCR product of each sample was first purified and then submitted in a quantity of 25 µL with 10 pmol of appropriate primer. The sequencing was performed by automated direct DNA sequencing technique, which incorporates fluorescently labeled dideoxy-nucleotides during cycle sequencing and separates the resulting products by capillary electrophoresis for detection on an ABI 3730XL DNA Analyzer (Applied Biosystems, USA). Multiple alignment and sequence analysis were done using BLAST, BioEdit, FinchTV, and Auto Assembler Software (Applied Biosystems, USA).
Variations were reconfirmed by sequencing amplicons in both directions and in independent second samples.
Results
A total of 58 cases were diagnosed as osteosarcoma according to Enneking et al. (19) and Bickels et al. (20) . The mean age of these patients was 20 ± 3.90 years, ranging from 10 years to 30 years. Four missense variations were detected in 25 osteosarcoma cases in exons 2, 4, and 5 and one silent variation was detected in two osteosarcoma cases in exon 3 (Figures 2-5 ). One missense variation was detected in exon 2 (Arg47Trp), one silent variation in exon 3 (Lys152Lys), one missense variation in exon 4 (Phe213Leu), and two missense variations in exon 5 (Gly315Arg and Asp339Asn). We observed the CYR61 gene missense variation rates in grade G1 (33.33% in a total of 10/30 cases), grade G2 (43.75% in a total of 7/16 cases), and grade G1/G2 (66.67% in a total of 8/12 cases). CYR61 gene silent variations were found in grade G1 (6.67% in a total of 2/30 cases). Details of the clinical data and missense and silent variations in exons 2, 3, 4, and 5 are shown in Table 3 . Out of 58 osteosarcoma cases, 39 were found to have variations by a shift in DNA position on SSCP-PAGE with respect to DNA from healthy donors ( Figure 1 ). These results, after comparison to previously reported findings, are shown in Table 4 . The CYR61 gene missense variation in exon 3 for codon Lys152Lys, exon 4 for codon Phe213Leu, and exon 5 for codons Gly315Arg and Asp339Asn are described here for the first time. Table 2 . PCR programs of different exons of the CYR61 gene.
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Step 1 (denaturation)
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Analysis of variations in exons 2, 3, 4, and 5
In 58 osteosarcoma cases, 25 samples showed a shift in position in native SSCP-PAGE in exon 2. These were directly sequenced by an automated sequencer. Eleven missense variations were detected in 11 osteosarcoma patients (Figures 2-4 ; Table 3 ). Out of 58 osteosarcoma cases, 10 samples displayed a shift in position in native SSCP-PAGE in exon 3. These were directly sequenced by an automated sequencer. Two silent variations were detected in two osteosarcoma patients (Figures 2-4 ; Table 3 ).
In 58 osteosarcoma cases, 13 samples showed a shift in position in native SSCP-PAGE in exon 4. These were directly sequenced by an automated sequencer. Five missense variations were detected in five osteosarcoma patients (Figures 2-4 ; Table 3 ). Out of 58 osteosarcoma cases, 23 samples showed a shift in position in native SSCP-PAGE in exon 5. These were directly sequenced by an automated sequencer. Nine missense variations were detected in nine osteosarcoma patients (Figures 2-4 ; Table 3 ).
For these findings, where we found variations around the protein, it was important to address where in the protein these variations were located in order to determine the possible implications of these variations in protein function. Therefore, we analyzed the protein sequence using BioEdit and Pyre2 software. The Arg47Trp variation for exon 2 is located on the insulin-like growth factor binding protein domain (IGFBP), the Lys152Lys silent variation for exon 3 is located on the von Willebrand factor domain (VWC), the Phe213Leu variation for exon 4 is located on the thrombospondin-homology domain (TSP-1), and the Gly315Arg and Asp339Asn variations for exon 5 are located on the cysteine knot domain (CT) in osteosarcoma cases.
Discussion
To our knowledge, this study is the first in northern India to report variations of the CYR61 gene in osteosarcoma patients. Osteosarcoma is the most common primary bone tumor. As it is a very fast-growing tumor with metastasis in early stages, it becomes difficult to diagnose it in initial stages. In almost all cases, micrometastasis in the pulmonary system has already taken place by the time a clinical diagnosis is made. This tumor is resistant to a number of chemotherapeutic agents, which is responsible for the treatment failure and high mortality rate of patients.
Previous molecular studies revealed several variations in different types of patients from different ethnic groups. Variations in exons 2, 3, and 4 of the CYR61 gene are less frequently detected than in exon 5 in different types of patients (23) (24) (25) . However, during our variation analysis, besides the detection of one missense variation in exon 2 (Arg47Trp), there was one silent variation in exon 3 (Lys152Lys), one missense variation in exon 4 (Phe213Leu), and two missense variations in exon 5 (Gly315Arg and Asp339Asn). The overall CYR61 variation frequency in exons 2, 3, 4, and 5 was determined to be 46.55% (27/58). With these observations, our study supports the role of CYR61 gene variation in osteosarcoma, and we concluded that by virtue of its behavior in osteosarcoma patients, this gene is justified for use as a prognostic/diagnostic marker. We also recommend the CYR61 gene as a new drug target for the treatment of osteosarcoma, though further multicenter studies are needed to validate this. As the CYR61 gene is located in 1p22.3 on chromosome 1, which has numerous translocations, it is reported to be the most common region of chromosome involvement in human cancers (26) , especially in osteosarcoma cells, which have a high percentage of polysomy in chromosome 1 (27) .
Wittig et al. (28) suggested CYR61 as a candidate gene responsible for drug resistance in melanoma. Overexpression of CYR61 was observed to increase the potential of resistance to chemotherapeutic drugs in ovarian and breast cancer cells (29, 30) . Later on Fromigue et al. (31) observed the antitumoral effect of the treatments targeting the CYR61 gene, which also enhances the potential of chemotherapy in bone tumors.
Fromigue et al. (31) also noticed the expression level of CYR61, which is significantly higher in primary osteosarcoma than in normal bone tissue. The CYR61 expression positively correlates with tumor invasiveness in human osteosarcoma and attenuation of CYR61 reduces cancer cell progression. Fromigue et al. also showed that the overexpression of the CYR61 gene increases the tumor behavior in osteosarcoma by acting on pulmonary metastatic foci, both in number and size.
High expression levels of CYR61 were reported in malignant melanomas, rhabdomyosarcomas, colon adenocarcinomas, and bladder papillomas (21, 32) . According to Xie et al., CYR61 also exhibited high levels in malignant gliomas, which enhanced the tumorigenicity (33) . Overexpression of CYR61 was recently identified in peritoneal metastases from human pancreatic cancer (34) . We also found a positive association of the CYR61 gene with osteosarcoma, which raises speculation that CYR61 might play distinct roles in osteosarcoma with different stages.
In conclusion, using a translational approach, we identified the missense variations (F213L and G315R) in osteosarcoma patients with linkage to CYR61, an important factor in carcinogenesis and its subsequent progression. The present study supports an important role of the CYR61 gene in human osteosarcoma and we recommend further multicenter studies with large sample sizes to confirm the roles of these variations in osteosarcoma patients and to establish an association. This gene can also provide a molecular target that will open the fields for a novel and effective therapeutic strategy to reduce the mortality and morbidity associated with the disease. The results signify that the CYR61 gene might be used as a prognostic/ diagnostic marker in osteosarcoma patients.
